Home » Market News » DirectorsTalk Highlights » Kromek awarded two extension contracts from European and US customers
Kromek

Kromek awarded two extension contracts from European and US customers

Kromek Group (LON:KMK), a worldwide supplier of detection technology focusing on the medical, security screening and nuclear markets, ihas today announced that it has been awarded two extension contracts relating to its D3S family of products and technologies designed to counter nuclear terrorism. The contracts are worth an aggregate of approximately £1.6m and will be delivered in this current financial year.

Arnab Basu, CEO of Kromek, commented: “The D3S family of products is gaining increasing momentum globally, with sales in 18 countries, as governments continue to adopt innovative solutions for countering the threat of nuclear terrorism. We are also pleased to be receiving further orders from existing customers, which reflects the value that they gain from our solutions. With some of our multi-year trials approaching a successful conclusion, we look forward to additional product and system-level sales of this leading-edge solution in the future.” 

The US Government’s Countering Weapons of Mass Destruction Office, which is a component within the US Department of Homeland Security, has awarded Kromek a $0.7m (c. £0.6m) extension contract to add further technical innovation capability to the D3S family of products. The enhancements will provide greater operational capability by improving user experience and add a specialised reporting function to generate further information for homeland security organisations.  

The Group has also been awarded a £1.0m contract extension by a European government-related company to provide integration of Kromek’s D3S-related technologies. The customer is a company that works with a European government to detect and protect against potential nuclear threats, and the Group’s solutions will be used for wide-area threat monitoring. This brings the total awarded by this customer during this financial year to £2.1m.

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.